The world's largest market research store, Research & Markets, recently released its annual Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights. The report covers the following key areas in the field of emerging prostate cancer vaccine research and development: Introduction to Prostate Cancer Vaccine Mechanism of Prostate Cancer Vaccine Global Prostate Cancer Vaccine Market Dynamics Global Prostate Cancer Vaccine Market Outlook Global Prostate Cancer Vaccine Market Future Prospects Personalized Cancer Vaccine Market Opportunities Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase Marketed Prostate Cancer Vaccines by Company & Country Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials Competitive Landscape Prostate cancer vaccines are a recent medical development, and have the potential to prevent cancer recurrence through the generation of an efficient immunological memory. Furthermore, it can decrease mortality rates associated with this malignancy and increase patients' overall survival. In this report, several biotechnology companies, along with their respective pipeline products are mentioned, including: Adamis Pharmaceuticals (San Diego, CA) - TeloB-VAX vaccine is composed of the patients' own circulating B lymphocytes harboring a unique patented engineered plasmid DNA. Aduro Biotech (Berkeley, CA) - ADU-741 drug works through the company's proprietary live-attenuated double-deleted (LADD) technology. The technology increases the body’s initial immune response and alerts tumor specific T cells. Bellicum Pharmaceuticals (Houston, TX) - BPX-201 is an autologous therapy, in which the patient’s own white blood cells are ext